Ads
related to: myeloma treatment guidelines- Treatment Results
See Treatment Results
From A Clinical Trial.
- Side Effect Info
Learn More About
Possible Side Effects.
- Treatment Results
Search results
Results from the WOW.Com Content Network
The preferred treatment for those under the age of 65 is high-dose chemotherapy, commonly with bortezomib-based regimens, and lenalidomide–dexamethasone, [106] to be followed by a stem cell transplant. A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107]
Members of the IMWG conduct research to prevent onset of myeloma, improve treatment and find a cure. [8] The working group publishes statements and treatment guidelines in its own name [9] as well as sponsoring publications by its members. The IMF also has the Black Swan Research Initiative (BSRI) in order to work towards finding a cure for ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. [6] [4]The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis ...
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone. [8] It is taken by mouth. [8]
Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. [8] [12] Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. [8] [12] [13] [14] Elranatamab is given by subcutaneous injection. [8] [12]
Other guidelines for the use of serum free light chain measurement in the management of AL amyloidosis, [42] plasmacytoma [43] and the comparison of treatment responses in clinical trials [44] have also been published. Technical and clinical reviews of serum free light-chain measurement have recently been written by Pratt and Jagannath. [45] [46]
MPNs arise when precursor cells (blast cells) of the myeloid lineages in the bone marrow develop somatic mutations which cause them to grow abnormally. There is a similar category of disease for the lymphoid lineage, the lymphoproliferative disorders acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma. [4]
Ads
related to: myeloma treatment guidelines